[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 15, 2000

Sources of Bias in the Economic Analysis of New Drugs

Author Affiliations
 

Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor

JAMA. 2000;283(11):1423-1424. doi:10.1001/jama.283.11.1421

To the Editor: Mr Friedberg and colleagues1 found that studies sponsored by drug companies were less likely to report unfavorable results than studies funded by nonprofit organizations. The authors posited several alternative explanations for their findings, including publication bias, unconscious bias because of relationships between the investigator and the pharmaceutical company, early screening of studies by drug firms, and direct company involvement with the study design.

First Page Preview View Large
First page PDF preview
First page PDF preview
×